These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 6083507

  • 1. [Hepatic clearance of 99mTc-p-butyl HIDA in liver diseases. Correlations with routine hematochemical parameters of liver function].
    Custro N, De Francisci MC, Patanella I, Scafidi V, Indovina I.
    Minerva Med; 1984 Nov 03; 75(42):2527-32. PubMed ID: 6083507
    [Abstract] [Full Text] [Related]

  • 2. [Clinico-diagnostic significance of the determination of bile acids in chronic liver diseases].
    Andreuzzi B, Vai C, Santese R, Andreuzzi P, Cantoni L.
    Minerva Med; 1984 Mar 31; 75(13):749-56. PubMed ID: 6717831
    [Abstract] [Full Text] [Related]

  • 3. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT, Marigold JH, Thompson RP.
    Hepatogastroenterology; 1982 Apr 31; 29(2):55-7. PubMed ID: 7084884
    [Abstract] [Full Text] [Related]

  • 4. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease.
    Wittayalertpanya S, Israsena S, Thamaree S, Tongnopnoua P, Komolmit P.
    Tokai J Exp Clin Med; 1996 Dec 31; 21(4-6):195-201. PubMed ID: 9300980
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R, Brachtel D, Gallenkamp H, Hofstetter G, Klinker H, Zilly W, Richter E.
    Z Gastroenterol; 1993 Feb 31; 31 Suppl 2():56-61. PubMed ID: 7483716
    [Abstract] [Full Text] [Related]

  • 7. Serum metabolite/caffeine ratios as a test for liver function.
    Jodynis-Liebert J, Flieger J, Matuszewska A, Juszczyk J.
    J Clin Pharmacol; 2004 Apr 31; 44(4):338-47. PubMed ID: 15051740
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K.
    Am J Gastroenterol; 1991 Jan 31; 86(1):41-5. PubMed ID: 1986553
    [Abstract] [Full Text] [Related]

  • 9. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts.
    Koruk M, Onuk MD, Akçay F, Savas MC.
    Hepatogastroenterology; 2002 Jan 31; 49(48):1645-8. PubMed ID: 12397754
    [Abstract] [Full Text] [Related]

  • 10. Long-term clinical investigation of the hepatobiliary agents: 99mTc-HIDA and 99mTc-p-butyl-IDA.
    Agha NH, Al-Hilli AM, Dahir ND, Al-Hissoni MS, Jasim MN, Miran KM, Shubber AH.
    Nuklearmedizin; 1986 Oct 31; 25(5):181-7. PubMed ID: 3797257
    [Abstract] [Full Text] [Related]

  • 11. 13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis.
    Fasoli A, Giannini E, Botta F, Romagnoli P, Risso D, Celle G, Testa R.
    Hepatogastroenterology; 2000 Oct 31; 47(31):234-8. PubMed ID: 10690614
    [Abstract] [Full Text] [Related]

  • 12. A simple method for routine determination of the metabolic liver capacity: the aminopyrine breath test.
    Haustein KO, Schenker E.
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr 31; 23(4):190-6. PubMed ID: 3922902
    [Abstract] [Full Text] [Related]

  • 13. Validity of 13C-phenylalanine breath test to evaluate functional capacity of hepatocyte in patients with liver cirrhosis and acute hepatitis.
    Koeda N, Iwai M, Kato A, Suzuki K.
    Aliment Pharmacol Ther; 2005 Apr 01; 21(7):851-9. PubMed ID: 15801920
    [Abstract] [Full Text] [Related]

  • 14. [Plasma clearance of cholic acid in patients with chronic diseases of the liver].
    Medrzejewski W, Habior A, Samociuk-Medrzejewska B, Cwikła M.
    Pol Tyg Lek; 2005 Apr 01; 45(16-18):335-7. PubMed ID: 2235721
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of liver disease on urine caffeine metabolite ratios.
    Denaro CP, Wilson M, Jacob P, Benowitz NL.
    Clin Pharmacol Ther; 1996 Jun 01; 59(6):624-35. PubMed ID: 8681487
    [Abstract] [Full Text] [Related]

  • 20. The expression of bcl-2 in chronic liver diseases.
    Mutluay R, Ozenirler S, Poyraz A.
    Saudi Med J; 2005 Aug 01; 26(8):1245-9. PubMed ID: 16127523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.